Royalty Report: Drugs, HPV, Disease – Collection: 273473

License Grant

University hereby agrees to grant and does grant to Company, subject to the terms and conditions hereof, an irrevocable, world-wide, exclusive, royalty-bearing license with the right to grant sublicenses under the Licensed Patents to make, have made, use, sell, offer to sell, or import Licensed Products.

License Property

United States Patent No. 5,643,715 – Human papillomavirus type 52 DNA sequences and methods for employing the same

United States Patent No. 5,057,411 – Type-specific papillomavirus DNA sequences and peptides

Field of Use

This agreement pertains to the drug industry relating to diseases associated with human papillomaviruses (“HPV”).  Human papillomavirus is the most common sexually transmitted infection.

License Grant

Licensor hereby grants to United Kingdom Licensee and its Affiliates an exclusive, royalty-bearing license throughout the Territory, with the right to grant sublicenses in accordance with the terms of this Agreement, under Licensors interest in the Licensor Patents, Licensor Technology and Joint Inventions, to develop, register, use, make, have made, import, export, offer to sell, sell and have sold HPV Vaccines and/or Antigens and/or Process.  Licensee agrees that it will use Licensor Technology and Licensor Patents only as licensed under this Agreement.

License Property

HPV Vaccine shall mean a vaccine for the prevention, control or treatment of human papilloma virus infection in humans in any formulation, configuration or delivery system or a product or process for the diagnosis of HPV infection in humans.

Antigen shall mean (i) HPV antigens and/or (ii) HPV proteins and/or (iii) other physical forms based on such antigens, such as peptides and/or nucleic acid(s) (DNA, RNA) delivered in any form including recombinant vectors.

Vaccine Product shall mean an HPV Vaccine (x)covered in whole or in part by a Licensor Patent or an Licensee Patent which covers Licensee Special Technology and/or (y) which incorporates or is derived from the use of Licensor Technology and/or Licensee Special Technology.  

Licensor Patents shall mean
5,298,418 – Cell line isolated from larval midgut tissue of Trichoplusia ni
5,300,435 – Trichoplusia ni cell line which supports replication of baculoviruses
5,437,951 – Self-assembling recombinant papillomavirus capsid proteins

Licensor Technology shall mean information, know-how and materials, including, but not limited to, pharmaceutical, chemical and biological products, technical and non-technical data and information (i) owned by Licensor and/or to which Licensor has a transferable interest on the Effective Date and/or at any time during the term of this Agreement and (ii) which relate to the field of L1 based HPV Vaccines and/or which arise from the Research Program, and in each case which are necessary or useful for the development, manufacture, use or sale of an HPV Vaccine.

Field of Use

Field of use is for the treatment for the human papilloma virus (AHPV@) (HPV).

Human papillomavirus (HPV) is the most common sexually transmitted infection (STI).
Many people with HPV don't develop any symptoms but can still infect others through sexual contact. Symptoms may include warts on the genitals or surrounding skin.
There's no cure for the virus and warts may go away on their own. Treatment focuses on removing the warts. A vaccine that prevents the HPV strains most likely to cause genital warts and cervical cancer is recommended for boys and girls.

License Grant

The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants to Licensee a worldwide, royalty-bearing exclusive license under the Licensed Patent and the Biological Material within the Field to make, have made, use and sell Licensed Product. The license does not include a sublicense right to Third Parties.

License Property

Licensed Patent means US patent No. 5.981.173 relating to Two Novel Genital Human Papillomavirus (HPV) types, HPV68 and HPV70, related to the Potentially Oncogenic HPV39 attached hereto in Exhibit 1 and all continuations-in-part as the case may be.

US patent No. 5,981,173 – Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39

HPV means Human Papillomavirus.  It's the most common sexually transmitted infection. HPV is usually harmless and goes away by itself, but some types can lead to cancer or genital warts.

Biological Material means biological material accession No. I-1540 of the cloned genome of the Human Papillomavirus type 68 (HPV68).

Licensed Product means HPV Hybrid Capture(R) II (HPV HCII) and/or any other product using the Licensed Patent and/or the Biological Material or fragments thereof, or derived biological material from Biological Material or fragments thereof, or a synthetic molecule corresponding to said Biological Material or to derived Biological Material or to fragments of both thereof.

Field of Use

Field means HPV in vitro human diagnostics and HPV in vitro pre-clinical and clinical diagnostic testing for HPV vaccine and therapeutic discovery and development.

License Grant

University hereby grants to Licensee and Licensee hereby accepts from University a sole and exclusive, royalty-bearing right and license for the territory under patent rights to make, have made, use, import, offer to sell, sell or have sold on its behalf product in the field, including the right to sublicense third parties.  Licensee shall have the right to extend such license to its affiliates.

Licensee, at Universitys request, shall grant to a third party a royalty bearing, sublicense under Patent Rights in the field defined by Licensee and the third party.  Licensee shall be required to grant only one sublicense under this Agreement.

License Property

Patent Rights shall mean the following German Patent Aplications P44 35 907.1-41, filed 7 October 1994, entitled 'Papillomavirusanliche Paertikel.  Fusionsproteine sowie Verhafen zo deren Herstellung,' 95 26 752.4 filed 21 July 1995, entitled 'Hochefflziente Bultung Von Papillomavirusanlichen Partikelein,' and the PCT Application EP95/03794 (W096/11272) filed 9 October 1995, entitled 'Papilloma virus-like particles, fusion proteins as well as processes for their production,' United States Patent Application filed 6 October, 1997 entitled 'Papillomavirus capsomere vaccine formulations and methods for use and any United States or foreign patent applications later filed based on the inventions (hereinafter referred to as the Patent Rights Patent Applications(s)' and any foreign or United States patents issuing from said pending or later filed patent applications (hereinafter referred to as the Patent Rights Patent(s)', and any continuations, continuations-in-part, divisions, reissues, reexaminations or extension of any of the foregoing.

Inventions shall mean new and useful improvements in  the construction of Papillomavius hybrid particles conceived and reduced to practice by all employees of University, and disclosed to University in University Invention Disclosure dated September 28, 1994, and December 16, 1996, and as amended from time to time.

Field of Use

Field shall mean products and processes directed to the treatment, prevention or diagnosis of human diseases or infections related to human papilloma virus ('HPV').

License Grant

The Parties agreed to amend and restate several sections of the original agreement to include but not limited to the following

Licensor hereby grants non-exclusive licenses (other than the Co-exclusive License for Therapeutic Immunization for HPV Antigens granted in this Agreement C below) in accordance with the terms stated herein.

In consideration of the obligations assumed by Licensee hereunder, Licensor hereby grants to Licensee and to any affiliates of Licensee the following licenses without the right to sublicense as set forth in this paragraph under technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the territory and in the field all products and/or compinations, subject to the following

(A1) For prophylactic immunization within the field, Licensor grants a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HPV Antigens
HBV Antigens
Influenza Antigens
Chlamydia Antigens
Mycobacterium Antigens
RSV Antigens
Malaria Antigens
Steptococcus pneumonia Antigens

(A2) For prophylactic immunization within the field, Licensor grants to Licensee a non-exclusive license for the following licensed antigens and no other antigens.

HIV Antigens

(B) For therapeutic immunization within the field, Licensor grants Licensee a non-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HBV Antigens
Chlamydia Antigens
Mycobacterium Antigens

(C) For therapeutic immunization within the field, licensor grants Licensee a co-exclusive license for the following licensed antigens (including combinations thereof) and no other antigens.

HPV Antigens

The regulatory and development milestone payments and the patent royalties for each Licensed Antigen in the non-exclusive licenses granted in (A1) and (B) shall be reduced by a certain percent.

License Property

The Products are for therapeutic immunization relating to infectious diseases that such as

HBV  – hepatitis B virus
HPV – human papillomavirus
HIV – human immunodeficiency virus

Field of Use

This agreement pertains to the drug industry.

License Grant

Licensor grants, and shall cause its Affiliates to grant, to Licensee the sole and exclusive, right and license, including a sublicense under the MIT Agreement, under the Licensor Technology to develop, use, offer for sale, sell and import Target Product in the Territory excluding Canada; and (b) Licensor grants, and shall cause its Affiliates to grant, to Licensee the sole and exclusive, right and license including a sublicense under the MIT Agreement, under the Licensor Technology to develop, use, offer for sale, sell and import Target Product in Canada.

The exclusivity of the foregoing license shall be subject to the retained right of Licensors and their respective Affiliates to practice the Licensor Technology for the purpose of conducting development, manufacture and commercialization of Target Products in the Territory to the extent expressly contemplated by this Agreement.

License Property

HspE7 shall mean any fusion protein containing (a) a human papilloma virus (HPV) E7 antigen, or an antigenic fragment, mutein or conjugate thereof, and (b) a bacterial stress protein, or a fragment, mutein or conjugate thereof, including, in particular and without limitation, that recombinant DNA derived fusion protein containing 638 amino acids, derived from the 65kDa heat shock protein of mycobacterium bovis var. BCG (Hsp65) coupled at the C-terminus to the E7 protein of human papilloma virus (HPV) type 16.  HspE7 includes nucleic acid sequences and vectors and host cells containing nucleic acid sequences encoding such proteins contained therein.

Licensor Technology shall mean the Licensor Know-How and the Licensor Patent Rights..
Licensor Patent Rights shall mean all Patents that Licensor  Controls as of the Execution Date or during the Term, including, without limitation, Patents that claim Licensor Inventions and/or Joint Inventions, which, in the absence of the license granted to Licensee under this Agreement, would be infringed by the making, using, selling, offer for sale or importation of Target Products in the Territory.  The Agreement lists all Licensor Patent Rights existing as of the Execution Date (Base Patents).

US Patent #6,338,952 – Stress proteins and uses therefor
US Patent #6,335,183 – Stress proteins and uses therefor

Field of Use

HspE7 targets a broad spectrum of human papillomavirus ('HPV') related diseases.

License Grant

Under an Option and License Agreement and Amendment, with the University, Licensee acquired license rights to a total of three patents, two relating to Licensee CoFactor product and one relating to Selone, both of which are intended for use in connection with cancer chemotherapy.

With this agreement the University grants Licensee the exclusive rights to conduct various technical, pre-clinical, marketing, patent, and other studies on products in the field of use during a six (6) month period commencing on the effective date of this Agreement.

The University grants to Licensee
—  the exclusive worldwide license in the field of use to use the patent to manufacture and sell the product; and
—  the right to grant sublicenses to any patent licensed exclusively, provided that any sublicensee agrees to be bound by the terms and conditions of this Agreement.

License Property

CoFactor(TM), for Anticancer, is a 5-FU biomodulator.
  
CoFactor (5,10 methylenetetrahydrofolate) is a patented new drug which greatly improves the performance of 5-FU (5-Fluorouracil) and other fluoropyrimidines commonly used in cancer chemotherapy.

Selone(TM), for  Anticancer, is an alkylating agent for drug-resistant cancers.   Selone is the Licensees leading compound in a new class of compounds which are potential new cancer drugs for drug resistant cancer, discovered through the University research focused on the use of the element selenium, an anti-oxidant. We are the exclusive licensee of a patent from the University, which encompasses the use of Selone and other oxygen-carbon-selenium compounds as anticancer agents, as well as the method for their synthesis.

Field of Use

The field of use shall mean all fields.  Licensee does biomedical research and development on treatments for cancer and viral infections.  Licensees goal is to become a leading developer of drug therapies for HIV/AIDS, HPV (human papillomavirus) and cancer.